Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.48 |
| ▸ | ARG2 | P78540 | 4/20 | 0.44 |
| ▸ | ARG1 | P05089 | 3/20 | 0.44 |
| ▸ | NOS2 | P35228 | 5/20 | 0.44 |
| ▸ | NOS1 | P29475 | 5/20 | 0.44 |
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | BHMT | Q93088 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4758907 | 0.98 | GSR (0.47) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL5968392 | 0.98 | GSR (0.47) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL3858559 | 0.98 | GSR (0.47) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL29579375 | 0.98 | GSR (0.47) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL2218978 | 0.95 | GSR (0.46) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL12463782 | 0.95 | GSR (0.46) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL29891046 | 0.95 | GSR (0.46) | GSRARG2ARG1NOS2NOS1 | |
| Aminocaproic Acid SCHEMBL5715910 | 0.89 | GSR (0.54) | GSRNOS2CYP1A2BHMTTSHR | |
| SCHEMBL5716598 | 0.89 | GSR (0.54) | GSRNOS2CYP1A2BHMTTSHR | |
| SCHEMBL130831 | 0.87 | SLC1A1 (0.52) | GSRCYP1A2BHMTBLMGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112823855-B | Preparation method of reverse osmosis composite membrane | 万华化学集团股份有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-112823855-A | Preparation method of reverse osmosis composite membrane | 万华化学集团股份有限公司 | 2021-05-21 | — | — | CN | claimed |
| CN-110551119-B | 6-Aminoacylamino n-hexanoyl carboline carboxylic acid benzyl ester, preparation and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-110551121-B | Glutamine amido n-hexyl carboline carboxylic acid benzyl ester, preparation, activity and application thereof | 首都医科大学 | 2020-11-27 | — | — | CN | claimed |
| CN-110551121-A | Glutamine amido n-hexyl carboline carboxylic acid benzyl ester, preparation, activity and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2019-12-10 | — | — | CN | claimed |
| CN-110551119-A | 6-Aminoacylamino n-hexanoyl carboline carboxylic acid benzyl ester, preparation and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2019-12-10 | — | — | CN | claimed |
| CN-110551120-A | 6-amino amido n-hexanoyl carboline benzyl carboxylate, preparation, activity and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2019-12-10 | — | — | CN | claimed |
| CN-101854804-B | Hdac inhibitors | LIXTE BIOTECHNOLOGY HOLDINGS INC | 2014-07-23 | — | — | CN | claimed |
| US-20120178783-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY, INC. | 2012-07-12 | — | — | US | claimed |
| US-8143445-B2 | HDAC inhibitors | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-03-27 | — | — | US | claimed |
| CN-101854804-A | HDAC inhibitor | LIXTE BIOTECHNOLOGY HOLDINGS INC | 2010-10-06 | — | — | CN | claimed |
| EP-2200439-A1 | HDAC INHIBITORS | Lixte Biotechnology, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| US-20090143445-A1 | HDAC Inhibitors | JOHN P. WHITE, ESQ | 2009-06-04 | — | — | US | claimed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| US-12636386-B2 | Compositions and methods for the treatment and imaging of cancer | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2026-05-26 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-5378691-A | Amino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-01-03 | — | — | US | disclosed |
| CN-1037155-A | Amino acid derivative | MERCK PATENT GMBH (DE) | 1989-11-15 | — | — | CN | disclosed |
| EP-0238202-A2 | Glycerol derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | GSR 1214/4885ARG2 1391/4885ARG1 1141/4885 |
| US-20120178783-A1 | HDAC INHIBITORS | HDAC3, HDAC4, HDAC7 | GSR 1435/4885ARG2 1434/4885ARG1 372/4885 |
| US-20090143445-A1 | HDAC Inhibitors | HDAC3, HDAC7, HDAC4 | GSR 1442/4885ARG2 1410/4885ARG1 360/4885 |
| US-12636386-B2 | Compositions and methods for the treatment and imaging of cancer | GBA1, GALC, CD47 | GSR 968/4885ARG2 1424/4885ARG1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.